Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

AIDS-Related Lymphoma (ARL): Pathophysiology, Subtypes, Presentation and Management

A hematology and infectious disease reference on how HIV creates a permissive environment for B-cell lymphoma, the main histologic subtypes, extranodal presentation, and contemporary chemoimmunotherapy with concurrent antiretroviral therapy.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This is the most accurate brief we have reviewed. The corrections below are omissions and points of emphasis rather than errors, and the core content stands as written.
  • Hodgkin lymphoma is named in the opening of the subtype section, correctly described as non-AIDS-defining and occurring at 5 to 15 times the background rate, and then left out of the subtype table. It deserves a row. In people with HIV it is more often mixed cellularity or lymphocyte-depleted, is almost always EBV-positive, presents at a more advanced stage with more marrow involvement, and is treated with standard Hodgkin chemotherapy alongside antiretroviral therapy. Unusually, its incidence did not fall in the ART era and in some analyses rose, which is worth stating because it runs against the pattern of everything else in the brief.
  • The rituximab caution reads as more current than it is. The concern about infectious deaths at CD4 counts below 50 came from an early randomized trial; subsequent studies with modern prophylaxis and infusional regimens supported its use even at low counts, and it is now routinely included for CD20-positive disease with monitoring. As written, a reader could conclude it is generally withheld at low CD4, which is no longer the case.
  • Zidovudine is not mentioned among antiretrovirals to avoid during chemotherapy. It is myelosuppressive and compounds chemotherapy-induced cytopenias, and is avoided for that reason alongside the CYP3A4 issue the brief covers well.
  • The drug interaction section correctly warns against ritonavir and cobicistat as CYP3A4 inhibitors. The reverse direction is missing: some antiretrovirals induce CYP3A4 and can lower chemotherapy exposure instead, which is why the whole regimen is reviewed rather than only the boosters.
  • Rasburicase is recommended for tumour lysis prevention without the one contraindication that matters. It causes severe haemolysis in people with G6PD deficiency and must not be given to them, so G6PD status is checked first.
  • The brief gives no account of the differential between primary CNS lymphoma and cerebral toxoplasmosis beyond noting that they must be distinguished. That distinction is one of the defining diagnostic problems in HIV medicine, and the tools that resolve it, EBV DNA by PCR on cerebrospinal fluid and functional imaging with PET or thallium SPECT, are worth naming, as is the historical empirical treatment trial still used where those are unavailable.
  • Immune reconstitution inflammatory syndrome is not mentioned. It can mimic both infection and progressing lymphoma in someone recently started on antiretroviral therapy, and it is a recognized source of diagnostic confusion in exactly this population.
  • PET-CT is listed for staging without the caveat that reactive and infectious nodal uptake is common in people with HIV, so scans are interpreted alongside the clinical picture rather than read in isolation.
  • Relapsed disease is not covered. Autologous stem cell transplant and CAR-T cell therapy are both now used in people with HIV, who were historically excluded from the trials that established them. That exclusion ending is a substantive change and affects what people should be asking about.
  • Fertility preservation is not mentioned, and it needs discussing before treatment starts rather than after.
  • The terminology point is worth making explicit. The brief uses AIDS-related lymphoma throughout, which is the formal term from the 1985 case definition. Many clinicians now say HIV-associated lymphoma because cases occur across the full range of CD4 counts in the treatment era, including in people with undetectable viral loads and normal counts.
  • Everything else in the brief is accurate and unusually well organized: that HIV does not infect the malignant B-cells but creates a permissive environment; loss of CD4 help impairing CD8 control of EBV-infected B-cells; gp120 and IL-6 and IL-10 driving polyclonal B-cell activation and error-prone somatic hypermutation and class switching; the resulting MYC, BCL2 and BCL6 translocations; EBV LMP1 and LMP2A mimicking CD40 and B-cell receptor signalling; KSHV v-cyclin and vIL-6 in primary effusion lymphoma; the CD4 context, viral association and clinical features given for each subtype; the extranodal predominance above 75 percent; the requirement for excisional or core biopsy rather than fine-needle aspiration; and the management principles including uninterrupted cART, PCP prophylaxis regardless of CD4 count, G-CSF support, HBV antiviral cover before rituximab, and intrathecal CNS prophylaxis in Burkitt lymphoma.

Download the PDF

All source documents